Small Molecules

05 May 2022 Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers
05 May 2022 Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
05 May 2022 Farxiga met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
04 May 2022 STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme
04 May 2022 Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
04 May 2022 Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
01 May 2022 U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms
01 May 2022 RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
28 Apr 2022 Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
28 Apr 2022 Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
26 Apr 2022 Priothera Receives FDA clearance of Investigational New Drug (IND) to start Phase 2b/3 study with mocravimod in Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
24 Apr 2022 New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
20 Apr 2022 SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
20 Apr 2022 SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
20 Apr 2022 BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
15 Apr 2022 Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
13 Apr 2022 Adiso Therapeutics Announces Completion of First Cohort Enrollment in a Phase 1b Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
13 Apr 2022 Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders
13 Apr 2022 Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
13 Apr 2022 OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting
12 Apr 2022 Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma
12 Apr 2022 Linnaeus Therapeutics Announces Presentation of Pre-Clinical Data of LNS8801 at 2022 AACR Annual Meeting
12 Apr 2022 Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
11 Apr 2022 InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients
11 Apr 2022 Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin's Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top